Travere Therapeutics (NASDAQ:TVTX) EVP Peter Heerma Sells 8,282 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) EVP Peter Heerma sold 8,282 shares of the firm’s stock in a transaction dated Thursday, September 17th. The stock was sold at an average price of $65.07, for a total value of $538,909.74. Following the transaction, the executive vice president directly owned 117,066 shares in the company, valued at approximately $7,617,484.62. The trade was a 6.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Peter Heerma also recently made the following trade(s):

• On Tuesday, September 15th, Peter Heerma sold 102,190 shares of Travere Therapeutics stock. The shares were sold at an average price of $62.26, for a total value of $6,362,349.40.
• On Wednesday, September 16th, Peter Heerma sold 172,717 shares of Travere Therapeutics stock. The shares were sold at an average price of $63.43, for a total value of $10,955,439.31.

Travere Therapeutics Trading Up 2.0%

NASDAQ:TVTX opened at $64.74 on Friday. The stock’s 50 day moving average price is $61.63 and its 200 day moving average price is $48.50. The company has a market capitalization of $6.10 billion, a PE ratio of -140.74 and a beta of 1.05. The company has a quick ratio of 3.99, a current ratio of 4.05 and a debt-to-equity ratio of 24.58. Travere Therapeutics, Inc. has a 52-week low of $22.06 and a 52-week high of $68.73.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings results on Tuesday, August 4th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.13) by $0.03. Travere Therapeutics had a negative return on equity of 55.15% and a negative net margin of 7.35%.The company had revenue of $169.58 million for the quarter, compared to analyst estimates of $157.27 million. During the same quarter in the previous year, the company posted $0.13 earnings per share. The firm’s revenue was up 48.2% compared to the same quarter last year. On average, research analysts anticipate that Travere Therapeutics, Inc. will post -0.54 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts recently commented on TVTX shares. TD Cowen upped their price target on shares of Travere Therapeutics from $60.00 to $75.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. HC Wainwright raised their price objective on shares of Travere Therapeutics from $57.00 to $67.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Wells Fargo & Company lifted their price objective on shares of Travere Therapeutics from $50.00 to $65.00 and gave the company an “overweight” rating in a research note on Friday, June 12th. Evercore set a $78.00 target price on shares of Travere Therapeutics in a report on Monday, August 10th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Travere Therapeutics in a research note on Monday, August 17th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $68.00.

Travere Therapeutics News Summary

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: Brokerages have assigned Travere Therapeutics a consensus rating of “Moderate Buy,” indicating that analysts generally continue to see upside potential in the stock. Travere Therapeutics Given Consensus Rating of Moderate Buy by Brokerages
• Neutral Sentiment: Company management will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 24. The event could provide updates on Travere’s rare-disease pipeline and commercial outlook, but no new operating information was announced. Travere Therapeutics to Present at the Stifel 2026 Virtual Immunology and Inflammation Forum
• Negative Sentiment: Multiple insiders, including the CEO, CFO, CAO and EVPs, reduced their holdings, with individual ownership declines ranging from about 7% to 60%. Although the sales were prearranged, concentrated insider selling may raise questions about near-term sentiment and limit the stock’s momentum.

Institutional Investors Weigh In On Travere Therapeutics

Hedge funds have recently modified their holdings of the stock. S&CO Inc. acquired a new position in Travere Therapeutics in the 2nd quarter valued at $3,181,000. Artia Global Partners LP acquired a new stake in shares of Travere Therapeutics in the 2nd quarter worth $19,260,000. Profund Advisors LLC lifted its stake in shares of Travere Therapeutics by 209.3% in the 4th quarter. Profund Advisors LLC now owns 62,604 shares of the company’s stock worth $2,392,000 after acquiring an additional 42,366 shares during the period. Quantinno Capital Management LP boosted its holdings in shares of Travere Therapeutics by 354.4% in the first quarter. Quantinno Capital Management LP now owns 68,317 shares of the company’s stock valued at $2,030,000 after acquiring an additional 53,283 shares in the last quarter. Finally, Elmind Capital LP purchased a new stake in shares of Travere Therapeutics in the second quarter valued at about $16,622,606.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare kidney and immune-mediated diseases. The company’s work is centered on conditions with significant unmet medical needs, including diseases that can lead to progressive kidney damage and kidney failure.

Travere’s principal commercial product is FILSPARI (sparsentan), an oral therapy for adults with primary immunoglobulin A nephropathy, or IgA nephropathy, who are at risk of disease progression.